Back to Top

"One of today's leaders in investor relations and shareholder services"

Tag Archives: ADMD

8-2-16 SmallCapVoice Interview with Advanced Medical Isotope Corp. (ADMD)

Advanced Medical Isotope Corp. (ADMD)

CEO and Chairman James C. Katzaroff and Dr. Darrell Fisher of Advanced Medical Isotope Corporation (or “AMI”) (ADMD), a late stage radiation oncology focused medical device company, called in to SmallCapVoice.com, Inc. to discuss their advances with their RadioGel (TM) product and the future plans for the product. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The Company intends to outsource material aspects of manufacturing, distribution, sales and marketing for its products in the United States and to enter into licensing arrangements outside of the United States, though the Company will evaluate its alternatives before finalizing its plans. For more information, please visit our website, www.isotopeworld.com.

This interview may …

Continue Reading

Posted in Interviews| Tagged |

4-26-16 SmallCapVoice Interview with Advanced Medical Isotope Corporation (ADMD)

Advanced Medical Isotope Corporation (ADMD)

AMI Founder, CEO and Chairman James C. Katzaroff and Dr. Albert Denittis both called in to SmallCapVoice.com, Inc. to discuss the applications, benefits and markets for the Y-90 RadioGel(TM) device. The Y-90 RadioGel(TM) device is one of several Y-90 brachytherapy products in development by AMI that may provide a safer, quicker and less expensive treatment to certain cancers including tumors deemed inoperable. Brachytherapy is the use of radiation to destroy cancerous tumors by placing a radiation source inside or next to the treatment area. According to Global Industry Analysts, by 2016 the U.S. brachytherapy market will reach $2 billion. Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The …

Continue Reading

Posted in Interviews| Tagged |

4-11-16 SmallCapVoice Interview with Advanced Medical Isotope Corporation (ADMD)

Advanced Medical Isotope Corporation (ADMD)

AMI Founder, CEO and Chairman James C. Katzaroff and Dr. Alice Villalobos, DVM, FNAP, Company chairperson of AMI’s new Veterinary Medicine Advisory Board called in to SmallCapVoice.com, Inc. to go over the exciting new markets and news for the Company. Recently ADMD announced the formation of a new, wholly-owned subsidiary, IsoPet Solutions Corporation, to focus on the vibrant and expanding veterinary oncology market.

Advanced Medical Isotope Corporation (ADMD) is a late stage radiation oncology focused medical device company engaged in the development of yttrium-90 based brachytherapy devices for the treatment of non resectable tumors. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. The IsoPet Solutions division is focused on establishing the infrastructure necessary to provide product to veterinary clinics including regulatory clearances and compliance as well as providing product awareness and education to veterinary oncologists. The Company intends to outsource …

Continue Reading

Posted in Interviews| Tagged |

11-6-13 SmallCapVoice Interview with Advanced Medical Isotope Corp. (ADMD)

James C. Katzaroff, CEO& Founder of Advanced Medical Isotope Corporation, called in to SmallCapVoice.com to discuss the recent announcement that ADMD has filed pre-market notification to the FDA pursuant to Section 510(k) of the U.S. Food, Drug and Cosmetic Act for its Yttrium-90 RadioGel(TM) patented brachytherapy cancer product.

Advanced Medical Isotope Corporation (ADMD) is a company engaged in the production and distribution of medical isotopes for advanced diagnostic and non-surgical therapeutic application. AMIC’s goal is to empower physicians, medical researchers, and ultimately patients by providing them with essential medical isotopes that, until recently, have not been feasible or economical, in an effort to detect and cure human disease. For more information, please visit our website, www.isotopeworld.com

Posted in Interviews| Tagged |

8-20-13 SmallCapVoice Interview with Advanced Medical Isotope Corp. (ADMD)

James C. Katzaroff, CEO & Founder of Advanced Medical Isotope Corporation (ADMD), called into SmallCapVoice.com to go over some big news for the Company regarding the FDA process they are in as well as the financial results for the best quarter for the Company to date! Advanced Medical Isotope Corporation is a Washington State based company comprised of a brilliant team of radio-chemists, scientists and engineers, collaborating with national labs and universities to implement proprietary technologies capable of producing crucial medical isotopes on US soil.

By enabling physicians and empowering researchers to find isotope solutions, we are helping to lengthen the lives of Cancer patients and creating hope for a healthier future.

Posted in Interviews| Tagged |

Advanced Medical Isotope Corporation, as Commercialization Partner, Receives Washington State Life Sciences Discovery Fund Grant to Further Recently Licensed Technology

Project Title is Injectable Radiogels for High-Dose Therapy of Non-Resectable Solid Tumors

KENNEWICK, Wash., April 20, 2012 (GLOBE NEWSWIRE) — Advanced Medical Isotope Corporation (AMIC) is the commercialization partner for a $148,880 grant from the Life Sciences Discovery Fund, a Washington state agency established in May 2005 which makes grant investments in innovative life sciences research to benefit Washington and its citizens. Funding for commercialization grant awards comes from Washington’s allocation of payments under the Master Tobacco Settlement Agreement of 1998, revenues arising from multi-state litigation with tobacco product manufacturers.

Continue Reading

Posted in Client News| Tagged |